Company / Operating Cash Flow per Share
CytomX Therapeutics, Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$0.55
FY2025
5-year range
-$1.82 / -$0.55
FY2021-FY2025
Trend
+49.1%
vs FY2024
Sector context
#105 of 212
Health Care
What the data says
At $-0.55, CytomX Therapeutics, Inc.'s operating cash flow per share ranks #105 of 212 in the Health Care sector. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-3.09 in FY2019 to $4.43 in FY2017.
Based on SEC 10-K filings.
-0.55 in FY2025.
Improved from $-0.83 to $-0.55 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#105 of 212 in Health CareTop 50% of 212This company -$0.55 Sector average -$14.72
▼
+96.3% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 49.1% year-over-year.
- Ranks #105 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2017.
- Lowest operating cash flow per share in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.55 | +49.1% |
| FY2024 | -$1.08 | -29.3% |
| FY2023 | -$0.83 | +50.2% |
| FY2022 | -$1.67 | +8.1% |
| FY2021 | -$1.82 | -1675.6% |
| FY2020 | $0.12 | +103.7% |
| FY2019 | -$3.09 | -84.2% |
| FY2018 | -$1.68 | -137.8% |
| FY2017 | $4.43 | +8051.2% |
| FY2016 | -$0.06 | +99.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026